MedTrace Logo

Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer

NCT00619996 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2009-02-26

No results posted yet for this study

Summary

The purpose of this study is to use Sorafenib plus Docetaxel to evaluate pharmacodynamics (PD) in Patients with prostate cancer.

Conditions

Interventions

DRUG

Sorafenib (Nexavar)

Sorafenib 400 mg bid orally continuously Sorafenib will be administered from the start of treatment in combination with Docetaxel until progression of disease.

DRUG

Docetaxel

Docetaxel 75 mg/mq ev g1 every 21 days. Docetaxel will be administered for a maximum of 9 cycles.

Sponsors & Collaborators

  • Italian Trial in Medical Oncology

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-01-31
Completion
2009-01-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00619996 on ClinicalTrials.gov